Every story in this section, newest first — page 76 of 373.
Lanvin Group (NYSE:LANV) reported unaudited first-half 2026 revenue of approximately €101 million, down 12.9%–13.4% year over year as the company continued its brand transformation and retail network optimization.
Zhihu (NYSE:ZH) reported unaudited second-quarter 2026 revenue of RMB690.1 million, down year over year from RMB716.9 million but up 5.9% compared with the previous quarter.
Li Auto (NASDAQ:LI) reported second-quarter 2026 revenue of RMB25.7 billion, down 15.1% year over year, as vehicle deliveries declined 11.5% to 98,330 units.
Global stocks edged higher on Wednesday as Brent crude prices fell more than 2% to $86.45 per barrel, easing some inflation concerns linked to disruptions around the Strait of Hormuz.
UP Fintech (NASDAQ:TIGR) reported record second-quarter 2026 revenue of US$182.3 million, up 31.4% year over year and 17.7% quarter over quarter, supported by higher trading activity and growth in client assets.
JOYY (NASDAQ:JOYY) reported unaudited second-quarter 2026 revenue of US$590.8 million, up 16.3% year over year, supported by growth across social entertainment, advertising, and e-commerce operations.
Biohaven (NYSE:BHVN) signed an exclusive global licensing agreement with SK Biopharmaceuticals for its Kv7 platform valued up to $795 million.
DSC (NASDAQ:DSC) reported unaudited second-quarter 2026 revenue of RMB167 million, up 3.7% year over year, while its GAAP net loss widened to RMB240.5 million after IPO-related expenses and share-based compensation.
TORM (NASDAQ:TRMD) reported a $338 million Q2 net profit as Strait of Hormuz disruptions elevated freight rates.
Deere & Company (NYSE:DE) announced that its Board of Directors declared a quarterly dividend of $1.62 per share, payable to eligible shareholders.
Intuit (NASDAQ:INTU) reported fiscal 2026 revenue of $21.4 billion, up 14% year over year, with higher revenue across its Global Business Solutions, Online Ecosystem, and Consumer businesses.
SpaceX (NASDAQ:SPCX) announced plans to launch its first AI-powered satellite systems in Q4 2027, with the company developing orbital computing infrastructure using Nvidia (NASDAQ:NVDA) technology.
Formula Systems (NASDAQ:FORTY) reported second-quarter 2026 revenue of $782.4 million, a record level and a 29.8% increase year over year, with higher operating income and shareholder earnings from continuing operations.
Huntsman (NYSE:HUN) and Olin (NYSE:OLN) announced that shareholders of both companies approved proposals required to complete their all-stock merger of equals, which will create OlinHuntsman Corporation.
BeOne Medicines (NASDAQ:ONC) received U.S. FDA approval for TEVIMBRA (tislelizumab) combined with ZIIHERA (zanidatamab) and chemotherapy as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals (NASDAQ:JAZZ) received U.S. Food and Drug Administration approval for two Ziihera (zanidatamab-hrii) treatment regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
Anavex Life Sciences (NASDAQ:AVXL) reported third fiscal quarter 2026 results and provided updates on blarcamesine development programs targeting Alzheimer’s disease, Rett syndrome, and Fragile X syndrome.
Vyome Holdings (NASDAQ:HIND) reported second-quarter 2026 results and provided a corporate update, highlighting progress on VT-1953, its lead program for symptoms associated with malignant fungating wounds.
OrthoPediatrics (NASDAQ:KIDS) announced the full commercial launch of its 3P Pediatric Plating Platform Hip System in the United States after a limited launch phase that included more than 350 surgical implantations.
BioCryst (NASDAQ:BCRX) announced that Japan’s Ministry of Health, Labor and Welfare approved once-daily ORLADEYO (berotralstat) as a preventive treatment for pediatric hereditary angioedema (HAE) patients aged 2 to under 12 years.
Sagimet Biosciences (NASDAQ:SGMT) reported progress on its AURORA U.S. Phase 3 clinical trial evaluating denifanstat, a FASN inhibitor being developed for moderate to severe acne.
Beyond Air (NASDAQ:XAIR) entered a definitive agreement for UNIVO Pharmaceutical Industries to acquire control of NeuroNOS Israel, a neurology-focused biopharmaceutical company in which Beyond Air owns approximately 58% of fully diluted shares.
The Bank of Nova Scotia (NYSE:BNS) reported fiscal third-quarter 2026 net income of C$2.95 billion, up from C$2.53 billion a year earlier, with higher revenue and earnings growth across business segments.
Lotus Technology (NASDAQ:LOT) completed the acquisition of 100% of the equity interests in Lotus Advance Technologies Sdn Bhd, known as Lotus UK, bringing its British sports car operations and engineering capabilities under a single corporate structure.
